Continuous first-line ofatumumab therapy for up to 6 years in recently diagnosed relapsing multiple sclerosis patients decreased the annualized relapse rate from 0.112 at Year 1 to 0.030 at Year 6.
RCT (n=409)
randomised
Does ofatumumab provide long-term safety and efficacy in recently diagnosed treatment-naive patients with relapsing multiple sclerosis?
First-line ofatumumab demonstrates sustained efficacy and a favorable safety profile over 6 years in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis.
BACKGROUND: We report ofatumumab's longer-term safety and efficacy in recently diagnosed (≤3 years) treatment-naive (RDTN) people living with relapsing multiple sclerosis (plwRMS). METHODS: Safety analyses included RDTN participants receiving at least 1 ofatumumab dose in ASCLEPIOS I/II or other ALITHIOS feeder studies (APLIOS and APOLITOS). Efficacy analyses included participants randomised to ofatumumab in ASCLEPIOS I/II and treated continuously for up to 6 years. Efficacy outcomes include annualised relapse rate (ARR), MRI lesions, no evidence of disease activity-3 (NEDA-3), cognitive processing speed, and work status. RESULTS: The safety analysis included 409 RDTN plwRMS. Exposure-adjusted incidence rates of serious infections and malignancies did not increase to the cut-off date (25-Sep-2025) of 6 years. Over 6 years, mean IgG levels remained stable and IgG was above the lower limit of normal (LLN: 5.65 g/L) in 98.0% of participants at all assessments; mean IgM levels decreased but IgM remained above LLN (0.4 g/L) in 64.1% of participants at all assessments. Of 314 RDTN participants receiving ofatumumab in ASCLEPIOS I/II (efficacy analysis), 233 entered ALITHIOS, and at data cut-off 181 (77.7%, 181/233) were still receiving ofatumumab. ARR decreased from 0.112 (Year 1) to 0.030 (Year 6). An almost complete suppression of MRI lesions was observed up to Year 6. NEDA-3 at Year 6 was observed in 94.4% of participants. At 6 years, up to 70.6% of participants experienced clinically meaningful improvement in cognitive processing speed. Reduced work absenteeism versus baseline was observed. CONCLUSIONS: Findings support ofatumumab's highly favourable longer-term benefit-risk profile as first-line therapy for plwRMS.
Hauser et al. (Tue,) conducted a rct in relapsing multiple sclerosis (n=409). ofatumumab was evaluated on annualised relapse rate (ARR). Continuous first-line ofatumumab therapy for up to 6 years in recently diagnosed relapsing multiple sclerosis patients decreased the annualized relapse rate from 0.112 at Year 1 to 0.030 at Year 6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: